New monthly shot could tame kidney disease
NCT ID NCT07020923
First seen Apr 22, 2026 · Last updated Jun 22, 2026 · Updated 11 times
Summary
This study tests a drug called atacicept in 90 adults with IgA nephropathy, a kidney disease. Participants receive the drug every four weeks to see if it lowers harmful antibodies linked to the condition. The goal is to control the disease and prevent kidney damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BERGER DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Vera Therapeutics
Brisbane, California, 94005, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
atacicept
What this could lead to
If successful, this could point toward a monthly treatment option to control IgA nephropathy and reduce kidney damage.
What could go wrong
This is an early Phase 2 study with only 90 participants, so results may not confirm effectiveness or safety. The drug may not work as hoped or could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.